American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • Regulatory

Ovarian cancer treatment receives FDA approval

American Pharmacy News Reports | Jan 21, 2017
Ovarian cancer causes more deaths in the U.S. than any other gynecologic cancer.

Ovarian cancer patients who have a sensitivity to chemotherapy will soon have another option to treat their disease as the U.S. Food and Drug Administration has approved Avastin as an alternative to or supplement for chemotherapy. Read More »

FDA approves review of Genentech drug to treat advanced bladder cancer

American Pharmacy News Reports | Jan 21, 2017
Tecentriq has been made available to some people with advanced bladder cancer.

Biotech group Genentech scored a big victory as the U.S. Food and Drug Administration has granted a priority review of the company’s newest cancer-treating  drug, Tecentriq. Read More »

Treatment for extrerme nearsightedness receives FDA approval

American Pharmacy News Reports | Jan 21, 2017
With mCNV, abnormal blood vessels grow directly into the retina.

The U.S. Food and Drug Administration has approved the use of Lucentis, created by biotech company Genentech, for people suffering with severe nearsightedness. Read More »

Alexion receives orphan drug designation for PNH treatment

American Pharmacy News Reports | Jan 18, 2017
PNH leads to hemolysis, in which a person’s red blood cells are destroyed.

The U.S. Food and Drug Administration granted orphan drug designation to Alexion Pharmaceuticals for ALXN1210, a drug for treating patients with paroxysmal nocturnal hemoglobinuria. Read More »

Acucela treatment receives FDA orphan drug designation

American Pharmacy News Reports | Jan 14, 2017
“We are very pleased to receive FDA’s orphan drug designation for emixustat,” Acucela's Dr. Ryo Kubota said.

The U.S. Food and Drug Administration granted orphan drug designation to Acucela's leading drug candidate emixustat hydrochloride, which was created to treat Stargardt disease. Read More »

AcelRX submits FDA application for pain-reducing drug

American Pharmacy News Reports | Jan 10, 2017
Patients who took part in the study began to see improvement in their pain levels within 15 to 30 minutes.

AcelRX Pharmaceuticals recently submitted a new drug application to the U.S. Food and Drug Administration for ARX-04. Read More »

GUEST COMMENTARY: PBMs: Protecting Consumers and Employers From High Drug Prices

LocalLabs News Service | Jan 10, 2017

Marrk Merritt, president and CEO of the Pharmaceutical Care Management Association, writes, "The truth is PBMs reduce costs for payers and consumers by 30 percent or more and are part of the solution. It’s time for drug manufacturers to take responsibility for their own business mistakes instead of blaming others." Read More »

Endo International releases HCI generic injection drug in U.S.

American Pharmacy News Reports | Jan 8, 2017
HCI is the generic form of CellCept.

Endo International, PLC, a subsidiary of Par Pharmaceutical, recently released mycophenolate mofetil hydrochloride (HCI) in the U.S. following Food and Drug Administration approval of its Abbreviated New Drug Application. Read More »

Ablative application for Peregrine System Kit gains FDA acceptance

American Pharmacy News Reports | Dec 31, 2016
The study will enroll approximately 100 patients around the world to assess the device’s combination therapy to treat persistent hypertension.

Ablative Solutions' Investigational New Drug application for the Peregrine System Kit -- a catheter-based renal denervation that targets the delivery of alcohol to treat uncontrolled hypertension -- has been accepted by the U.S. Food and Drug Administration. Read More »

Argentina approves Hemispherx’s application for rintatolimod

Jeff Gantt | Dec 30, 2016
In Argentina, rintatolimod has been commercially approved for the severe disabling form of chronic fatigue syndrome.

Argentina's regulatory body has approved Hemispherx Biopharma's New Drug Application for the commercial sale of rintatolimod. Read More »

FDA grants designation to Primary Amebic Meningoencephalitis treatment

American Pharmacy News Reports | Dec 22, 2016
Miltefosine was developed to treat Primary Amebic Meningoencephalitis.

Profounda's miltefosine has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

EMA recommends approval for baricitinib

American Pharmacy News Reports | Dec 22, 2016
Baricitinib was developed to treat moderate-to-severe active rheumatoid arthritis.

Eli Lilly and Co., along with Incyte Corp., have announced that baricitinib received a positive opinion as well as a recommendation for approval from the European Medicines Agency Committee for Medicinal Products for Human Use. Read More »

AcelRx submits application for ARX-04 to FDA

American Pharmacy News Reports | Dec 15, 2016
AcelRx submitted an NDA for ARX-04 for the treatment of patients who experience moderate-to-severe acute pain in medical settings.

AcelRx Pharmaceuticals has submitted a New Drug Application for ARX-04 (sufentanil sublingual tablet, 30 mcg) to the U.S. Food and Drug Administration. Read More »

Cognition initiates CT1812 trial in U.S.

American Pharmacy News Reports | Dec 15, 2016
CT1812 was developed to treat Alzheimer's disease.

Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States. Read More »

Merck releases KEYNOTE-013 KEYTRUDA data

American Pharmacy News Reports | Dec 14, 2016
The data showed KEYTRUDA demonstrated an ORR of 41 percent.

Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma. Read More »

FDA grants velusetrag with Fast Track designation

American Pharmacy News Reports | Dec 11, 2016
Velusetrag received the designation due to its ability to treat gastroparesis.

Theravance Biopharma's velusetrag (TD-5108) has been granted Fast Track designation by the U.S. Food and Drug Administration. Read More »

Risankizumab granted Orphan Drug Designation by FDA

American Pharmacy News Reports | Dec 6, 2016
Risankizumab is being assessed for the treatment of immunological disorders such as Crohn’s disease.

AbbVie's risankizumab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the investigational treatment of pediatric patients who have Crohn’s disease. Read More »

Otsuka ABILIFY MAINENA sNDA under review by FDA

American Pharmacy News Reports | Dec 3, 2016
The supplemental New Drug Application for the expanded labeling of ABILIFY MAINENA has been completed.

Otsuka Pharmaceuticals and Lundbeck's supplemental New Drug Application for the expanded labeling of ABILIFY MAINENA has been completed and will receive a substantive review by the U.S. Food and Drug Administration. Read More »

Biological Industries receives FDA approval for NutriStem

American Pharmacy News Reports | Dec 3, 2016
The Drug Master File for NutriStem hPSC XF Medium has been accepted by the U.S. Food and Drug Administration.

Biological Industries' Drug Master File for NutriStem hPSC XF Medium has been accepted by the U.S. Food and Drug Administration. Read More »

FDA approves Armodafinil Tablets in U.S.

American Pharmacy News Reports | Dec 1, 2016
As of September, U.S. sales for Nuvigil Tablets, Armodafinil Tablet’s name brand counterpart, are $515.6 million.

The U.S. Food and Drug Administration has approved Armodafinil Tablets developed by Lupin Pharmaceuticals. Read More »

  • «
  • 1
  • 2
  • ...
  • 13
  • 14
  • 15
  • 16 (current)
  • 17
  • »
Trending

Anthony DiGiorgio, Assistant Professor of Neurological Surgery, UCSF

UCSF neurosurgery professor urges 340B reform: 'The incentives are totally misaligned'

Chris Sain President at North Carolina Board of Pharmacy

North Carolina updates rules on controlled substance disposal for pharmacies

 B. Douglas Hoey CEO

NCPA supports new bipartisan Senate bill targeting pharmacy benefit manager practices

Heath Veuleman, Healthcare Strategist at Seersucker Strategies

Healthcare Strategist on 340B exploitation: 'In any other industry, we’d call this money laundering'

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up